CLOs on the Move

Bio-Techne

www.bio-techne.com

 
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne`s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.bio-techne.com
  • 614 McKinley Place NorthEast
    Minneapolis, MN USA 55413
  • Phone: 612.379.2956

Executives

Name Title Contact Details
Trevor Woodage
Assistant General Counsel, Intellectual Property Profile
Shane Bohnen
Associate General Counsel Profile
Shane Bohnen
Senior Vice President and General Counsel Profile
Brenda Furlow
General Counsel Profile
Brenda Furlow
Executive Vice President, General Counsel and Chief Sustainability and Compliance Officer Profile

Similar Companies

Syndax

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.

MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.

CK Life Sciences Int'l. Inc

CK Life Sciences Int'l. Inc is a Kirkland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genpathway

Genpathway, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Intrinsic Medicine

Making Medicine From Milk